Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-04
2007-09-04
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
11035248
ABSTRACT:
The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6916815 (2005-07-01), Vite et al.
patent: 6933386 (2005-08-01), Bhide et al.
patent: 6951859 (2005-10-01), Bhide et al.
patent: 6969717 (2005-11-01), Bhide et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 7034151 (2006-04-01), Chen et al.
patent: 2003/0069244 (2003-04-01), Leftheris et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: 2005/0107462 (2005-05-01), Godfrey, Jr. et al.
patent: WO 00/71129 (2000-11-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 2004/009542 (2004-01-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Eskens, British Journal of Cancer 90: 1-7, 2004.
Migliara et al. J. Heterocyclic. Chem. 16: 833-834, 1979.
Patil et al. J. Heterocyclic. Chem. 31: 781-786, 1994.
Fan et al., Trend Pharcol. Sci., vol. 16, pp. 57-66 (1995).
Folkman, Nature Medicine, vol. 1, pp. 27-31 (1995).
Cullinan-Bove et al., Endocrinology, vol. 133, pp. 829-837 (1993).
Senger et al., Cancer and Metastasis Reviews, vol. 12, pp. 303-324 (1993).
DeVries et al., Science, vol. 255, pp. 989-991 (1992).
Terman et al., Biochem. Biophys. Res. Comm., vol. 187, pp. 1579-1586 (1992).
Jakeman et al., Endocrinology, vol. 133, pp. 848-859 (1993).
Kolch et al., Breast Cancer Research and Treatment, vol. 36, pp. 139-155 (1995).
Connolly et al., J. Biol. Chem., vol. 264, pp. 20017-20024 (1989).
Barbosa Stephanie
Bhide Rajeev S.
Cai Zhen-Wei
Lombardo Louis
Qian Ligang
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Korsen Elliott
LandOfFree
Inhibitors of kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737343